|1.||Yun, Yeo-Pyo: 8 articles (05/2013 - 01/2007)|
|2.||Johnson, Mahlon D: 7 articles (04/2015 - 01/2002)|
|3.||Lynch, Samuel E: 7 articles (07/2013 - 06/2003)|
|4.||Cao, Yihai: 7 articles (01/2013 - 05/2003)|
|5.||Kim, Tack-Joong: 7 articles (01/2011 - 01/2007)|
|6.||Heldin, Carl-Henrik: 6 articles (05/2013 - 04/2004)|
|7.||Kim, Bokyung: 5 articles (06/2015 - 03/2009)|
|8.||McGuire, Michael K: 5 articles (10/2014 - 12/2005)|
|9.||Hee, Christopher K: 5 articles (01/2014 - 01/2012)|
|10.||Ostman, Arne: 5 articles (04/2011 - 04/2004)|
|1.||Wounds and Injuries (Trauma)
11/01/2011 - "Research to date has shown that NorLeu(3)-A(1-7) is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. "
01/01/2008 - "Becaplermin plus good wound care may be cost effective in specific populations. "
03/01/2000 - "Becaplermin gel is the first topical growth factor to demonstrate therapeutic efficacy in the healing of diabetic wounds. "
03/01/2006 - "Our current study using commercially available Regranex failed to reproduce the previously reported finding that PDGF improved wound closure in healing impaired genetically diabetic mice."
01/01/2014 - "To mitigate the confounding variables that influence the efficacy of topically applied PDGF-BB, we used a controlled full thickness splinted excisional wound model in db/db mice (type 2 diabetic mouse model) for our investigations. "
12/01/2001 - "Recombinant human platelet derived growth factor-BB gel (PDGF gel) has been shown to be effective in the treatment of diabetic neuropathic ulcers. "
08/01/1998 - "Therefore, becaplermin gel appears to be a safe therapy for the treatment of lower extremity diabetic ulcers."
01/01/1995 - "Once-daily topical application of rhPDGF-BB is safe and effective in stimulating the healing of chronic, full-thickness, lower-extremity diabetic neurotrophic ulcers."
07/01/2000 - "Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study."
05/01/2000 - "Results of this study further confirm the efficacy and safety of becaplermin gel for the treatment of lower extremity diabetic ulcers."
06/01/2005 - "Although the sample size was not large enough to demonstrate that the incidence of healing in the OASIS group was statistically superior (P = .055), the study results showed that treatment with OASIS is as effective as Regranex in healing full-thickness diabetic foot ulcers by 12 weeks."
10/01/2002 - "Results of this analysis suggest that becaplermin may ultimately be more cost-effective for the treatment of chronic diabetic foot ulcers than other treatment modalities, despite its higher initial dollar cost. "
01/01/2001 - "Becaplermin may be a cost-effective treatment for neuropathic diabetic foot ulcers in a wide range of European settings. "
01/01/2001 - "Clinical studies on gene therapy for diabetic foot ulcers are only available for the local application of human recombinant PDGF-BB growth factor. "
05/01/2015 - "Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers."
03/01/2014 - "The combination of rhPDGF-BB and β-TCP represented a therapeutic combination that was effective in treating multiple gingival recession defects. "
11/01/2011 - "Minimally invasive treatment of maxillary anterior gingival recession defects by vestibular incision subperiosteal tunnel access and platelet-derived growth factor BB."
03/01/2014 - "A comparative evaluation of rhPDGF-BB + β-TCP and subepithelial connective tissue graft for the treatment of multiple gingival recession defects in humans."
04/01/2009 - "CTG and rhPDGF-BB + beta-TCP + wound-healing dressing are effective treatment modalities for clinically correcting gingival recession defects. "
02/01/2009 - "Gingival recession defects were surgically created in six premolar teeth with no more than 3 mm of keratinized marginal tissue, an osseous crest 2 to 3 mm apical to the newly created gingival margin, and recession depth of at least 3 mm. The defects were left untouched for 2 months; then, four defects were grafted with rhPDGF-BB + beta-TCP + a wound healing dressing, and two defects received CTGs. "
11/01/2000 - "Our proposed study is designed to assess local and systemic toxicity, and the feasibility of using the maximum tolerated dose of H5.020CMV.PDGF-b associated with in vivo platelet-derived growth factor-BB gene transduction via an intraulcer injection of H5.020CMV.PDGF-b in patients with a diabetic insensate foot ulcer."
03/01/2008 - "A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers."
01/01/2008 - "Becaplermin gel represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply. "
01/01/2008 - "Becaplermin gel in the treatment of diabetic neuropathic foot ulcers."
01/01/2009 - "Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?"
|1.||platelet-derived growth factor BB (becaplermin)
|2.||Platelet-Derived Growth Factor
|4.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|10.||Transforming Growth Factor beta (TGF-beta)
|4.||Homologous Transplantation (Allograft)